Michael Robert Ballinger

Array ( [id] => 17640614 [patent_doc_number] => 20220168352 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-02 [patent_title] => CAR T-CELL ADJUVANT THERAPIES [patent_app_type] => utility [patent_app_number] => 17/537687 [patent_app_country] => US [patent_app_date] => 2021-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11132 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17537687 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18879164 [patent_doc_number] => 20240002533 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => ARGINASE 1 BINDERS FOR INHIBITING ARGINASE 1 ACTIVITY [patent_app_type] => utility [patent_app_number] => 18/253691 [patent_app_country] => US [patent_app_date] => 2021-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24434 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18253691 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17640592 [patent_doc_number] => 20220168330 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-02 [patent_title] => ANTIBODY DRUG CONJUGATES [patent_app_type] => utility [patent_app_number] => 17/522623 [patent_app_country] => US [patent_app_date] => 2021-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27642 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17522623 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17702940 [patent_doc_number] => 20220202946 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => CEACAM5 ANTIBODY-DRUG CONJUGATE FORMULATION [patent_app_type] => utility [patent_app_number] => 17/522443 [patent_app_country] => US [patent_app_date] => 2021-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22647 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17522443 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17561751 [patent_doc_number] => 20220125900 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-28 [patent_title] => NEOANTIGENS IN CANCER [patent_app_type] => utility [patent_app_number] => 17/517118 [patent_app_country] => US [patent_app_date] => 2021-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42636 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -50 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17517118 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18816077 [patent_doc_number] => 20230390416 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-07 [patent_title] => COMPOSITIONS FOR INDUCING TUMOR IMMUNITY AND REDUCING DRUG TOLERANCE [patent_app_type] => utility [patent_app_number] => 18/032058 [patent_app_country] => US [patent_app_date] => 2021-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30720 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18032058 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18816020 [patent_doc_number] => 20230390359 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-07 [patent_title] => USE OF REELIN FOR TREATING CARDIAC DISEASES [patent_app_type] => utility [patent_app_number] => 18/249057 [patent_app_country] => US [patent_app_date] => 2021-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19898 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18249057 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17519287 [patent_doc_number] => 20220105135 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-07 [patent_title] => METHODS AND COMPOSITIONS FOR THE MODULATION OF OPIOID SIGNALING IN THE TUMOR MICROENVIRONMENT [patent_app_type] => utility [patent_app_number] => 17/494062 [patent_app_country] => US [patent_app_date] => 2021-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 94999 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17494062 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18666273 [patent_doc_number] => 11773151 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-03 [patent_title] => Ultra-long acting insulin-Fc fusion proteins and methods of use [patent_app_type] => utility [patent_app_number] => 17/488852 [patent_app_country] => US [patent_app_date] => 2021-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 42 [patent_no_of_words] => 41109 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17488852 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18953597 [patent_doc_number] => 20240041924 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => T CELL AND ANTIGEN-PRESENTING CELL ENGAGERS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/026297 [patent_app_country] => US [patent_app_date] => 2021-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50923 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18026297 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18428724 [patent_doc_number] => 11673934 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-13 [patent_title] => Ultra-long acting insulin-Fc fusion proteins and methods of use [patent_app_type] => utility [patent_app_number] => 17/488685 [patent_app_country] => US [patent_app_date] => 2021-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 42 [patent_no_of_words] => 41144 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17488685 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19462430 [patent_doc_number] => 20240316099 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-26 [patent_title] => CYTOTOXIC AND COSTIMULATORY CHIMERIC ANTIGEN RECEPTORS [patent_app_type] => utility [patent_app_number] => 18/245281 [patent_app_country] => US [patent_app_date] => 2021-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58920 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -525 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18245281 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18725840 [patent_doc_number] => 20230340065 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => PRAME SPECIFIC T-CELL RECEPTORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/028025 [patent_app_country] => US [patent_app_date] => 2021-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23072 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18028025 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18938151 [patent_doc_number] => 20240033290 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-01 [patent_title] => COMPOSITIONS AND METHODS FOR CD7 MODIFICATION [patent_app_type] => utility [patent_app_number] => 18/245793 [patent_app_country] => US [patent_app_date] => 2021-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22727 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -43 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18245793 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18901354 [patent_doc_number] => 20240016839 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-18 [patent_title] => BICISTRONIC INHIBITORY CHIMERIC ANTIGEN RECEPTOR (ICAR)/ACTIVATING CHIMERIC ANTIGEN RECEPTOR (ACAR) CONSTRUCTS FOR USE IN CANCER THERAPIES [patent_app_type] => utility [patent_app_number] => 18/044075 [patent_app_country] => US [patent_app_date] => 2021-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 78033 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -188 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18044075 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18893747 [patent_doc_number] => 20240009232 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => COMBINATION THERAPY COMPRISING HER-2-DC1 VACCINE AND A PROBIOTIC [patent_app_type] => utility [patent_app_number] => 18/021845 [patent_app_country] => US [patent_app_date] => 2021-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16991 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18021845 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18567112 [patent_doc_number] => 20230257441 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-17 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING CANCERS [patent_app_type] => utility [patent_app_number] => 18/020837 [patent_app_country] => US [patent_app_date] => 2021-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23202 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -52 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18020837 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19343570 [patent_doc_number] => 20240252533 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => METHODS AND COMPOSITIONS FOR PANCREATIC CANCER EVALUATION AND TREATMENT [patent_app_type] => utility [patent_app_number] => 18/040586 [patent_app_country] => US [patent_app_date] => 2021-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19539 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -106 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18040586 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17426883 [patent_doc_number] => 20220054591 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => METHODS OF TREATING OF INFLAMMATORY BOWEL DISEASE AND PARASITE INFECTION [patent_app_type] => utility [patent_app_number] => 17/390176 [patent_app_country] => US [patent_app_date] => 2021-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12173 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17390176 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18626752 [patent_doc_number] => 20230285558 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-14 [patent_title] => ENGINEERED T CELLS AND TUMOR-INFILTRATING LYMPHOCYTES TO INCREASE TUMOR KILLING [patent_app_type] => utility [patent_app_number] => 18/006652 [patent_app_country] => US [patent_app_date] => 2021-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23212 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18006652 [rel_patent_id] =>[rel_patent_doc_number] =>)